Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Complementary Role of Fibroblast Growth Factor 21 and Cytokeratin 18 in Monitoring the Different Stages of Nonalcoholic Fatty Liver Disease.

Wu G, Li H, Fang Q, Zhang J, Zhang M, Zhang L, Wu L, Hou X, Lu J, Bao Y, Jia W.

Sci Rep. 2017 Jul 11;7(1):5095. doi: 10.1038/s41598-017-05257-5.

2.

Discovery of Novel Insulin Sensitizers: Promising Approaches and Targets.

Chen Y, Ma H, Zhu D, Zhao G, Wang L, Fu X, Chen W.

PPAR Res. 2017;2017:8360919. doi: 10.1155/2017/8360919. Epub 2017 Jun 4. Review.

3.

Fibroblast Growth Factor 21 Deficiency Attenuates Experimental Colitis-Induced Adipose Tissue Lipolysis.

Liu L, Zhao C, Yang Y, Kong X, Shao T, Ren L, Zhuang X, Yin B, Dryden G, McClain C, Luan W, Feng W.

Gastroenterol Res Pract. 2017;2017:3089378. doi: 10.1155/2017/3089378. Epub 2017 May 11.

4.

Fibroblast Growth Factor 21 Mimetics for Treating Atherosclerosis.

Kwok KHM, Lam KSL.

Endocrinol Metab (Seoul). 2017 Jun;32(2):145-151. doi: 10.3803/EnM.2017.32.2.145. Epub 2017 May 19. Review.

5.

Metabolic role of fibroblast growth factor 21 in liver, adipose and nervous system tissues.

Lin X, Liu YB, Hu H.

Biomed Rep. 2017 May;6(5):495-502. doi: 10.3892/br.2017.890. Epub 2017 Apr 10.

6.

Identification of Sp1 as a Transcription Activator to Regulate Fibroblast Growth Factor 21 Gene Expression.

Chen S, Li H, Zhang J, Jiang S, Zhang M, Xu Y, Dong K, Yang Y, Fang Q, Jia W.

Biomed Res Int. 2017;2017:8402035. doi: 10.1155/2017/8402035. Epub 2017 Mar 29.

7.

Nuclear factor E2-related factor 2 knockdown enhances glucose uptake and alters glucose metabolism in AML12 hepatocytes.

Yuan X, Huang H, Huang Y, Wang J, Yan J, Ding L, Zhang C, Zhang L.

Exp Biol Med (Maywood). 2017 May;242(9):930-938. doi: 10.1177/1535370217694435. Epub 2017 Jan 1.

PMID:
28440735
8.

The hepatokine FGF21 is crucial for peroxisome proliferator-activated receptor-α agonist-induced amelioration of metabolic disorders in obese mice.

Goto T, Hirata M, Aoki Y, Iwase M, Takahashi H, Kim M, Li Y, Jheng HF, Nomura W, Takahashi N, Kim CS, Yu R, Seno S, Matsuda H, Aizawa-Abe M, Ebihara K, Itoh N, Kawada T.

J Biol Chem. 2017 Jun 2;292(22):9175-9190. doi: 10.1074/jbc.M116.767590. Epub 2017 Apr 12.

PMID:
28404815
9.

Mechanistic Investigations of the Mitochondrial Complex I Inhibitor Rotenone in the Context of Pharmacological and Safety Evaluation.

Heinz S, Freyberger A, Lawrenz B, Schladt L, Schmuck G, Ellinger-Ziegelbauer H.

Sci Rep. 2017 Apr 4;7:45465. doi: 10.1038/srep45465.

10.

Distinct but complementary contributions of PPAR isotypes to energy homeostasis.

Dubois V, Eeckhoute J, Lefebvre P, Staels B.

J Clin Invest. 2017 Apr 3;127(4):1202-1214. doi: 10.1172/JCI88894. Epub 2017 Apr 3. Review.

11.

Alcoholic fatty liver is enhanced in CYP2A5 knockout mice: The role of the PPARα-FGF21 axis.

Chen X, Ward SC, Cederbaum AI, Xiong H, Lu Y.

Toxicology. 2017 Mar 15;379:12-21. doi: 10.1016/j.tox.2017.01.016. Epub 2017 Jan 25.

PMID:
28131861
12.

Nutrigenomic Functions of PPARs in Obesogenic Environments.

Chung S, Kim YJ, Yang SJ, Lee Y, Lee M.

PPAR Res. 2016;2016:4794576. doi: 10.1155/2016/4794576. Epub 2016 Nov 30. Review.

13.

Obesity: An Immunometabolic Perspective.

Ray I, Mahata SK, De RK.

Front Endocrinol (Lausanne). 2016 Dec 12;7:157. doi: 10.3389/fendo.2016.00157. eCollection 2016. Review.

14.

An engineered FGF21 variant, LY2405319, can prevent non-alcoholic steatohepatitis by enhancing hepatic mitochondrial function.

Lee JH, Kang YE, Chang JY, Park KC, Kim HW, Kim JT, Kim HJ, Yi HS, Shong M, Chung HK, Kim KS.

Am J Transl Res. 2016 Nov 15;8(11):4750-4763. eCollection 2016.

15.

Epigenomic and transcriptional control of insulin resistance.

Rosen ED.

J Intern Med. 2016 Nov;280(5):443-456. doi: 10.1111/joim.12547. Epub 2016 Oct 14. Review.

PMID:
27739225
16.

The Bone Marrow-Derived Stromal Cells: Commitment and Regulation of Adipogenesis.

Tencerova M, Kassem M.

Front Endocrinol (Lausanne). 2016 Sep 21;7:127. eCollection 2016. Review.

17.

Hepatic Fgf21 Expression Is Repressed after Simvastatin Treatment in Mice.

Ziros P, Zagoriti Z, Lagoumintzis G, Kyriazopoulou V, Iskrenova RP, Habeos EI, Sykiotis GP, Chartoumpekis DV, Habeos IG.

PLoS One. 2016 Sep 1;11(9):e0162024. doi: 10.1371/journal.pone.0162024. eCollection 2016.

18.

PPARγ agonists promote differentiation of cancer stem cells by restraining YAP transcriptional activity.

Basu-Roy U, Han E, Rattanakorn K, Gadi A, Verma N, Maurizi G, Gunaratne PH, Coarfa C, Kennedy OD, Garabedian MJ, Basilico C, Mansukhani A.

Oncotarget. 2016 Sep 20;7(38):60954-60970. doi: 10.18632/oncotarget.11273.

19.

Fibroblast growth factor 21 deficiency exacerbates chronic alcohol-induced hepatic steatosis and injury.

Liu Y, Zhao C, Xiao J, Liu L, Zhang M, Wang C, Wu G, Zheng MH, Xu LM, Chen YP, Mohammadi M, Chen SY, Cave M, McClain C, Li X, Feng W.

Sci Rep. 2016 Aug 8;6:31026. doi: 10.1038/srep31026.

20.

The Orphan Nuclear Receptor ERRγ Regulates Hepatic CB1 Receptor-Mediated Fibroblast Growth Factor 21 Gene Expression.

Jung YS, Lee JM, Kim DK, Lee YS, Kim KS, Kim YH, Kim J, Lee MS, Lee IK, Kim SH, Cho SJ, Jeong WI, Lee CH, Harris RA, Choi HS.

PLoS One. 2016 Jul 25;11(7):e0159425. doi: 10.1371/journal.pone.0159425. eCollection 2016.

Supplemental Content

Support Center